Advancements of antisense oligonucleotides in treatment of breast cancer

Acta Pharmacologica Sinica

Volumn 24, Issue 4, 2003, Pages 289-295

  Yang, Shuan Ping ^a   Song, San Tai ^a   Song, Hai Feng ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Antisense oligonucleotides; Breast neoplasms; Oncogenes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOCETAXEL; GENE PRODUCT; INTEGRIN; OBLIMERSEN; OLIGONUCLEOTIDE 4259; OLIGONUCLEOTIDE 4625; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; REGULATOR PROTEIN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CELL VIABILITY; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIGENE FAMILY; NONHUMAN; ONCOGENE NEU; PROGNOSIS; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENE PROTEINS V-ERBB; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER;

EID: 0037385703     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cellfree translation. Proc Natl Acad Sci USA 1977; 74: 4370-4.
2. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285-8.
3. Simons RW, Kleckner N. Translational control of IS10 transposition. Cell 1983; 34: 683-91.
4. Liebhaber SA. mRNA stability and the control of gene expression. Nucliec Acids Symp Ser 1997; 36: 29-32,
5. Zhu YG, Zhuo GS, Chen ZZ, Chen XC. Cationic lipids enhanced cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells. Acta Pharmacol Sin 2001; 22: 1007-12.
6. Yuan SJ, Tang ZM, Song HF, Zhu BZ. Combination of antisense oligodeoxynucleotides against C-raf and PKC-α mRNA enhancing inhibition on the proliferation of A549 cell in vitro. Chin J Pharmacol Toxicol 2000; 14: 136-9.
7. Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA. Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev 1997; 16: 5-27.
8. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000; 182: 150-62.
9. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, et al. P185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-7.
10. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-47
11. Miles DW. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting. Breast Cancer Res 2001; 3: 380-4.
12. Bertram J, Killian M, Brysch W, Schlingensiepen KH, Kneba M. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem Biophys Res Commun 1994; 200: 661-7.
13. Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, et al. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 1995; 92: 8338-42.
14. Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. Synergistic anti-tumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery 1999; 126: 413-21.
15. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, et al. Overexpression of bcl-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997; 3: 230-7.
16. Reed JC: Prevention of apoptosis as a mechanism of drug resistance. Hem Onc Clinics North Am 1995; 9: 451-73.
17. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-23.
18. Chi KC, Wallis AE, Lee CH, de Menezes DL, Sartor J, Dragowska WH, et al. Effects of bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent bcl-2 protein expression. Breast Cancer Res Treat 2000; 63: 199-212.
19. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hollenstein U, Lucas T, et al. A phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (Genta) as a chemosensitizer in patients with advanced malignant melanoma (Abstract). Proc Am Asso Clin Oncol 1999;18:2049.
20. Simoes-Wust AP, Olie RA, Gautschi O, Leech SH, Haner R, Hall J, et al. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000; 87: 582-90.
21. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93: 463-71.
22. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmacol Ther 1993; 60: 265-88.
23. Miller WR, Watson DM, Jack W, Chetty U, Elton RA. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 1993; 26: 89-94.
24. Srivastava RK, Srivastava AR, Park YG, Agrawal S, Cho-Chung YS. Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Res Treat 1998; 49: 97-107.
25. Srivastava RK, Srivastava AR, Seth P, Agrawal S, Cho-Chung YS. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action. Mol Cell Biochem 1999; 195: 25-36.
26. Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, de Placido S, Bianco AR, et al. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer 2000; 85: 710-5.
27. Neckers LM. Regulation of transferrin receptor expression and control of cell growth. Pathobiology 1991; 59: 11-8.
28. Cairo G, Pietrangelo A. Transferrin receptor gene expression during rat liver regeneration. Evidence for post-transcriptional regulation by iron regulatory factor B, a second iron-responsive element-binding protein. J Biol Chem 1994; 269: 6405-9.
29. Yang DC, Head JF, Wang F, Elliott RL. Transferrin receptor mRNA and ferritin H-chain mRNA expression are associated with prognostic indicators for breast cancer. Proc Am Assoc Cancer Res 1997; 38: 419-20.
30. Yang DC, Jiang XP, Elliott RL, Head JF. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Res 2001; 21: 1777-87.
31. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549-54.
32. Green LJ, Mould AP, Humpries MJ. The integrin beta subunit. Int J Biochem Cell Biol 1998; 30: 179-84.
33. Meredith JE Jr, Wintitz S, McArthur Lewis J. The regulation of growth an intracellular signaling by integrins. Endocrine Rev 1996; 17: 207-20.
34. Meyer T, Marshall JF, Hart IR. Expression of αV integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer 1998; 77: 530-6.
35. Townsend PA, Villanova I, Uhlmann E, Peyman A, Knolle J, Baron R, et al. An antisense oligonucleotide targeting the alpha V integrin gene inhibits adhesion and induces apoptosis in breast cancer cells. Eur J Cancer 2000; 36: 397-409.
36. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001; 7: 3613-24.
37. DeMoor JM, Vincent MD, Collins OM, Koropatnick J. Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription. Exp Cell Res 1998; 243: 11-21.
38. Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997; 24: 187-202.
39. Robertson D. Crohn's trial shows the pros of antisense. Nat Biotechnol 1997; 15: 209.
40. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996; 40: 2004-11.
41. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, et al. Chemosensitization of malignant melanoma by BCL-2 antisense therapy. Lancet 2000; 356: 1728-33.
42. Song HF, Tang ZM, Yuan SJ, Zhu BZ. Application of secondary structure prediction in antisense drug design targeting protein kinase C-α mRNA and quantitative structure activity relationship analysis. Acta Pharmacol Sin 2000; 21: 80-6.
43. Song HF, Tang ZM, Yuan SJ, Zhu BZ. Activity prediction of antisense drugs designed against protein kinase C-α mRNA by QSAR equation. Chin J Pharmacol Toxicol 2000; 14: 401-4.
44. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol 1999; 181: 251-7.
45. Weiner GJ. CpD DNA in cancer immunotherpy. Curr Top Microbiol Immunol 2000; 247: 157-70.
46. Yang SP, Song ST, Song HF, Chang XF. Antisense oligonucleotides, a new class of drug for breast cancer therapy. J Tumor Marker Oncology 2001; 16: 361-2.